Description
Details
Cytiva® Plus Cardiomyocytes are derived from NIH Registered human Embryonic Stem Cells (hESC) and provide a biologically-relevant model for use in safety screening and risk assessment of compounds for cardiotoxic responses in drug discovery. Suitable for interrogation in multiparametic platforms such as high-content analysis (HCA) and multielectrode arrays (MEA), Cytiva Plus Cardiomyocytes form spontaneously beating monolayers when plated into microwell plates and exhibit appropriate morphology and electrophysiological responses when treated with known compounds.
Cytiva Plus Cardiomyocytes have been extensively characterized and functionally verified by flow cytometry, sub-cellular imaging and electrophysiology. Cells are provided cryopreserved in a ready-to-use format.
Cytiva Plus Cardiomyocytes have been extensively characterized and functionally verified by flow cytometry, sub-cellular imaging and electrophysiology. Cells are provided cryopreserved in a ready-to-use format.
Details
Details
Format | Frozen in 1.0 mL cryovials containing 10% DMSO and 90% fetal bovine serum |
---|---|
Size | 3.5X10⁶ viable cells |
Storage | Liquid nitrogen; vapor phase |
Expiration | Refer to the appropriate certificate of analysis |
Stem Cell Source | Cell Line WA07 (H7); NIH Approval # NIHhESC-10-0061 |
Characterization | Flow cytometry; sub-cellular imaging; electrophysiology |
Technical Documents | Cytiva Plus User’s Manual |
Legal | Gen 2 Cardiomyocytes are provided under license from GE Healthcare, UK Limited. |